Is NEOGENOMICS INC (NEO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 35.2% / 30% | 13.7% / 30% | 13.7% / 30% | 1.25% / 5% | ✗ NOT HALAL |
| DJIM | 35.2% / 33% | 13.7% / 33% | 13.7% / 33% | 1.25% / 5% | ✗ NOT HALAL |
| MSCI | 30.1% / 33% | 11.7% / 33% | 11.7% / 33% | 1.25% / 5% | ✓ HALAL |
| S&P | 35.2% / 33% | 13.7% / 33% | 13.7% / 33% | 1.25% / 5% | ✗ NOT HALAL |
| FTSE | 30.1% / 33% | 11.7% / 33% | 11.7% / 50% | 1.25% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 43.2% | |
| Operating Margin | -6.6% | |
| Net Margin | -14.9% | |
| Return on Equity (ROE) | -12.4% | |
| Return on Assets (ROA) | -2.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $5M |
| Free Cash Flow | -$22M |
| Total Debt | $409M |
| Debt-to-Equity | 48.9 |
| Current Ratio | 4.3 |
| Total Assets | $1.4B |
Price & Trading
| Last Close | $7.76 |
| 50-Day MA | $10.27 |
| 200-Day MA | $9.30 |
| Avg Volume | 1.9M |
| Beta | 1.6 |
|
52-Week Range
$4.72
| |
About NEOGENOMICS INC (NEO)
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is NEOGENOMICS INC (NEO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), NEOGENOMICS INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is NEOGENOMICS INC's debt ratio?
NEOGENOMICS INC's debt ratio is 35.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 30.1%.
What are NEOGENOMICS INC's key financial metrics?
NEOGENOMICS INC has a market capitalization of $933M, and revenue of $727M. The company maintains a gross margin of 43.2% and a net margin of -14.9%. Return on equity stands at -12.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.